LEADER 02394nam  2200625 a 450 
001 9910965123103321
005 20251116221042.0
010   $a1-61728-630-3
035   $a(CKB)2560000000068789
035   $a(EBL)3020732
035   $a(SSID)ssj0000467205
035   $a(PQKBManifestationID)12192775
035   $a(PQKBTitleCode)TC0000467205
035   $a(PQKBWorkID)10489987
035   $a(PQKB)10610926
035   $a(MiAaPQ)EBC3020732
035   $a(Au-PeEL)EBL3020732
035   $a(CaPaEBR)ebr10680870
035   $a(OCoLC)698081866
035   $a(BIP)30334057
035   $a(EXLCZ)992560000000068789
100   $a20100419d2010      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aBeneficial effects of perhexiline in cardiovascular disease states /$fYuliy Y. Chirkov, Aaron L. Sverdlov and John D. Horowitz
205   $a1st ed.
210   $aNew York $cNova Biomedical/Nova Science Publishers$d2010
215   $a1 online resource (53 p.)
225 1 $aCardiology research and clinical developments
300   $aDescription based upon print version of record.
311 08$a1-61668-977-3 
320   $aIncludes bibliographical references (p. [31]-38) and index.
327   $aClinical applications of perhexiline -- Pharmacokinetics and toxicity of perhexiline -- Pharmacology of perhexiline -- Conclusion and future perspectives.
330   $aPerhexiline, 2-(2,2-dicyclohexylethyl) piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. This book discusses the benefits of perhexiline in the treatment of cardiovascular disease.
410  0$aCardiology research and clinical developments series.
606   $aPerhexiline$xTherapeutic use
606   $aAngina pectoris$xChemotherapy
606   $aCardiovascular agents
615  0$aPerhexiline$xTherapeutic use.
615  0$aAngina pectoris$xChemotherapy.
615  0$aCardiovascular agents.
676   $a616.1/22061
700   $aChirkov$b Yuliy Y$01869606
701   $aSverdlov$b Aaron L$01869607
701   $aHorowitz$b John D$01869608
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910965123103321
996   $aBeneficial effects of perhexiline in cardiovascular disease states$94477801
997   $aUNINA